Since the Omnibus 1 Directive narrowed CSRD reporting scope earlier this year, many Irish pharmaceutical companies have been left wondering where they now stand. We take stock of what changed, who is still in scope, and what to watch for as the next milestone approaches.

Ireland's medical device sector is on track for a fresh wave of efficiency gains between now and 2031. We look at what's behind the numbers, from automation to cleanroom throughput, and what it could mean for manufacturing sites as the sector keeps evolving.

Decarbonising pharmaceutical manufacturing without compromising supply, compliance or product quality is one of the defining challenges facing Irish pharma sites right now. It was the subject of a dedicated session at the Future in Pharmaceuticals Ireland 2026 conference and it is a conversation that is only getting more urgent. Here is what it actually looks like in practice.

The BioPharmaChem Ireland Sustainability and Responsible Care Report 2026 shows the sector is growing its economic output while reducing its environmental footprint. Total energy consumption is down 3%, electricity-related CO2 is down 30% and VOC emissions have fallen 23% over three years. Here is what those numbers mean for Irish pharma manufacturers.

Ireland's pharmaceutical and biopharmaceutical sector has recorded a 30% reduction in electricity-related CO₂ emissions over the past three years, according to the BioPharmaChem Ireland Sustainability and Responsible Care Report 2026. For businesses tracking carbon performance and energy costs, this is a significant marker of what's possible when decarbonisation strategy is embedded at the operational level.